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Abstract
Background: Little is known about the impact of reclassification on patients’ per-
ception of medical uncertainty or trust in genetics-based clinical care.
Methods: Semistructured telephone interviews were conducted with 20 patients who 
had received a reclassified genetic test result related to hereditary cancer. All par-
ticipants had undergone genetic counseling and testing for cancer susceptibility at 
Vanderbilt-Ingram Cancer Center Hereditary Cancer Clinic within the last six years.
Results: Most of the participants did not express distress related to the variant re-
classification and only a minority expressed a decrease in trust in medical genetics. 
However, recall of the new interpretation was limited, even though all participants 
were recontacted by letter, phone, or clinic visit.
Conclusion: Reclassification of genetic tests is an important issue in modern health-
care because changes in interpretation have the potential to alter previously recom-
mended management. Participants in this study did not express strong feelings of 
mistrust or doubt about their genetic evaluation. However, there was a low level 
of comprehension and information retention related to the updated report. Future 
research can build on this study to improve communication with patients about their 
reclassified results.
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1 |  INTRODUCTION
Genetic testing for diagnosing and predicting disease has be-
come a mainstay of genetic medicine. The field is still young, 
and our knowledge of the relationship between genotype and 
human health is constantly evolving, such that understand-
ings of the clinical impact a patient's test result may change 
over time. Because of this, testing laboratories have devel-
oped internal protocols for variant interpretation, reinterpre-
tation, and communication of results with the ordering health 
care provider (Murray, Cerrato, Bennett, & Jarvik, 2011).
While there are many competing classification systems 
for annotating genetic variants (Halverson,  2019;Shoenbill, 
Fost, Tachinardi, & Mendonca, 2014), the American College 
of Medical Genetics and Genomics and the Association for 
Molecular Pathology recommend a five-tier classification sys-
tem based on the variants’ assumed pathogenicity (Richards 
et al., 2015). Interpretations of a pathogenic or likely patho-
genic variant in genes linked to human cancers may be clinically 
actionable, meaning that clinicians can implement specific 
measures to treat or prevent the development of the disorder 
(Turner, Rao, Morgan, Vnencak-Jones, & Wiesner,  2019). 
Furthermore, cascade testing of family members is usually 
recommended for pathogenic or likely pathogenic variants 
(Slavin, Manjarrez, Pritchard, Gray, & Weitzel, 2019).
Although all variant interpretations have the potential to 
change as more is learned, we (Turner et al., 2019) and others 
(Mersch et al., 2018;Slavin et al., 2019) have shown that re-
classification is not uncommon and can significantly alter the 
management of patients and their families. This is compli-
cated by the fact that there are differences among laboratories 
in their interpretations of specific genetic variants (Balmaña 
et al., 2016). Thus, discrepant classifications can be the result 
of broadly accepted shifts in interpretations of genetic data or 
of individual laboratories’ differential access to or acceptance 
of available research.
Most reclassifications take the form of the downgrading 
of variants of uncertain significance (VUSs) to the status of 
likely benign or benign, although it is possible that a patho-
genic variant can be downgraded to the status of likely benign 
or VUS as well (Mersch et  al.,  2018). The reinterpretation 
can indicate that the patient no longer meets the criteria for 
specific management guidelines based on the current under-
standings of the data (Mersch et al., 2018;Turner et al., 2019). 
Cascade testing might not be recommended for a downgraded 
variant, which then complicates the management of family 
members. Upgrading of VUSs also occurs and has more ob-
vious effects on care, making the patient eligible for interven-
tions that previously were not likely recommended.
Reclassification represents an added layer of uncer-
tainty for both practitioners’ and patients’ understanding 
of genetic information. Uncertainty in clinical knowledge 
has been linked to patients’ lack of trust in expert practice 
(Hong & You,  2016;Makhnoon, Garrett, Burke, Bowen, & 
Shirts, 2019). As has been reported regarding the disclosure 
of VUSs (Makhnoon et al., 2019;O’Neill et al., 2009), reclas-
sification has the potential to have negative effects on patient 
attitudes, including trust, anxiety, and understanding and to 
exacerbate intolerance for uncertainty among patients, thus 
leading to greater distress.
Little is known about patients’ experience with and un-
derstanding of variant reclassification. A study that enrolled 
family members for the purpose of resolving VUSs showed 
mixed reactions to reclassifications based on the type of re-
classification the patients received (Tsai et  al.,  2019). The 
same study also found that the disclosure of uncertain re-
sults led many participants to feel frustrated and to distrust 
their providers (Makhnoon et  al.,  2019). Far fewer studies 
have assessed patients’ responses to the reclassification of 
genetic results (Sexton, Rawlings, McKavanagh, Simons, & 
Winship, 2015;Wong et al., 2019). Yet an understanding of 
the reclassification is particularly important for patients with 
VUSs, as such variants, by definition, are inconclusive and 
are not meant to inform clinical decision making. However, 
both patients (Vos et  al.,  2008) and clinicians (McCullum, 
Bottorff, Kelly, Kieffer, & Balneaves, 2007;Vos et al., 2008) 
often inappropriately rely on these results to make decisions 
about surgery and screening that are inconsistent with cur-
rent guidelines for management (Eccles, Copson, Maishman, 
Abraham, & Eccles, 2015;Macklin, Jackson, Atwal, & 
Hines, 2019;Mersch et al., 2018). In some cases, patients opt 
for irreversible surgery prior to the downgrading of a VUS 
to the status of a benign variant (Garcia, Lyon, Littell, & 
Powell, 2014). These prior studies are important when taken 
together because they suggest that patients are making se-
rious decisions about their healthcare based on potentially 
insufficient data, and reclassification most often reveals that 
the intervention they have chosen to undergo is no longer 
clinically indicated.
Our limited understanding of patient responses to re-
classification is therefore concerning, leading us to wonder 
whether variant reclassification could adversely impact a 
patient's trust in medical genetics and in health care more 
broadly. In order to address this knowledge gap, we conducted 
a qualitative interview study of patients at Vanderbilt-Ingram 
Cancer Center who had received a reclassified genetic test 
result after previous testing for cancer susceptibility.
2 |  MATERIALS AND METHODS
2.1 | Participants
We conducted a qualitative study using semistructured inter-
views with patients evaluated and tested in the Vanderbilt-
Ingram Cancer Center's Hereditary Cancer Clinic within the 
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last six years and who had received amended reports with a 
reclassification of one or more genetic variants identified on 
the initial laboratory report. The method of communication 
followed clinic policy, where patients of clinically significant 
upgraded or downgraded results were called and then sent a 
follow-up letter with a copy of the updated laboratory report. 
Patients with a downgraded result that did not change current 
management practices (such as a VUS to LB) were notified by 
letter or patient portal. Participants were identified through a 
retrospective review of an IRB-approved, HIPAA-compliant 
Hereditary Cancer REDCap database (Turner et  al.,  2019) 
and invited to join the study by letter and follow-up phone 
call. REDCap is a Vanderbilt-developed, web-based appli-
cation used to manage online surveys and databases (Harris 
et al., 2009, 2019). Interviews were conducted over a 1-year 
period, between April 2018 and April 2019. This study re-
ceived approval from Vanderbilt University Medical Center's 
Institutional Review Board.
We sought to interview 20 patients who were 18 years of 
age or older and had valid contact information. Our sampling 
method was purposive, attempting to recruit as many partic-
ipants as possible whose results could have changed the clin-
ical relevance of the variant or altered clinical management 
(Turner et al., 2019). As stated, candidates were first sent an 
invitation letter, notifying them of the project and a phone 
number to call if they were interested in participating. Two 
weeks later, researchers began inviting these candidates by 
phone to enroll in the study. Contact by phone was attempted 
with candidates up to three times. Those who wished to par-
ticipate completed an oral consent and scheduled a mutually 
acceptable time for the phone interview. A separate REDCap 
database was created with participants’ contact information, 
clinical data, and genetic test results. Participants were of-
fered a $25 online gift certificate in appreciation for their 
time.
2.2 | Interview guide
We developed an in-depth, semistructured interview guide, 
which is available in the Data Supplement. In consultation 
with experienced methodologists and qualitative research-
ers at Vanderbilt University, our team developed the guide 
iteratively, designed based on a review of literature related 
to issues of reclassification, the return of results, and clinical 
uncertainty.
The interview guide addresses three primary topics and 
collects participants’ demographics. First, it asks participants 
to describe their case history, including a discussion of both 
the initial genetic test results and the reclassification. Second, 
it explores participants’ comprehension of these results. 
Finally, it captures the psychosocial impact of the reclassifi-
cation on the participant.
2.3 | Data analysis
Phone-recorded interviews were conducted by an experi-
enced interviewer trained in qualitative methods (CMEH) 
using the interview guide. Recruitment continued until 
thematic saturation was reached. All interviews were pro-
fessionally transcribed verbatim and de-identified. Each 
participant was given a pseudonym, consisting of a ran-
domly assigned number and an annotation of the original 
and reclassified category of their result (P  =  pathogenic, 
LP  =  likely pathogenic, U  =  VUS, LB  =  likely benign, 
B  =  benign). Grounded theory was used to analyze the 
interviews in order to ascertain common themes across 
participants’ experiences (Strauss & Corbin,  1998). Two 
authors (CMEH, BCW) developed a code list after cod-
ing an initial subset of transcripts. All authors deliberated 
over the themes and patterns that emerged from the inter-
views, and coding was refined through an iterative process. 
Two authors (CMEH, BCW) then coded all transcripts. 
Conflicts in interpretation were discussed with the whole 
team and resolved by consensus.
3 |  RESULTS
3.1 | Respondents
Initially, 41 individuals met enrollment criteria. Twenty of 
these candidates consented and completed an interview, re-
sulting in a total response rate of 49%. Participants had been 
notified of the reclassification between two and six years 
prior to the interview, with an average of four years hav-
ing passed. The demographics of the study population are 
fairly representative of the patient population in the clinic 
who had a result reclassified. Only one man (5%) completed 
the interview, while men make up the minority in the pa-
tient population as well (15%). The cohort included six 
African Americans (30%; 7% of the patient population) and 
14 Caucasians (70%; 75% of the patient population). Ages 
ranged from 35 to 70, with an average age of 51. Six of the 
participants (30%) had had reclassifications that, according 
to current recommendations, warranted a change in surveil-
lance or treatment (Turner et al., 2019). The plurality (9, or 
45%) had a genetic test result associated with an increased 
risk for developing breast cancer. (These final data points are 
not available for the broader patient population.) For more 
demographic information, see Table 1.
3.2 | Means of recontact
Our participants were evaluated at the Hereditary Cancer 
Clinics and received pre- and post-test genetic counseling. 
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They were sent personal notification of any reclassification 
of their genetic test results. We confirmed that all 20 par-
ticipants with whom we interviewed had received written or 
oral communication with this reclassification information. 
Nine of the interviewees had also directly communicated 
with a clinician either over the phone or in clinic about the 
reclassification.
Participants were first made aware of their reclassification 
in a number of different ways, following clinic policy for re-
contact depending on whether the variant was up- or down-
graded. Surprisingly, some of the participants recalled being 
contacted directly by the laboratory; others did not recall the 
reclassification. In some instances, the genetics specialist 
called the patient before sending the updated genetic test re-
port. In other instances, participants received only a letter by 
mail or a message through the online patient portal.
One participant in her 30s learned of the reclassification 
through a family member. She had initially undergone ge-
netic testing because of her strong family history of breast 
and ovarian cancers and was told that she had a pathogenic 
BRCA2 mutation. Because of the increased lifetime risk for 
developing breast cancer, her surgeon recommended a double 
mastectomy and reconstruction. Shortly before her scheduled 
surgery, her niece underwent genetic testing at a different 
clinic, using a different laboratory. The niece had the same 
BRCA2 variant, but her laboratory categorized it as a VUS, 
therefore making it clinically insufficient to warrant the in-
vasive prophylactic surgical interventions. Confused by this 
discrepancy, the participant contacted her genetic clinician, 
who had not been informed about the change in interpreta-
tion, which had occurred in the time between the participant's 
and her niece's tests. “It makes me feel unnerved,” she ex-
plained (03P > U). Because the laboratory used for this par-
ticipant had not notified the clinic of the reclassification, the 
only way she could have learned of it was through her niece's 
serendipitous report. Had both relatives been tested by the 
first laboratory, the participant suspects that she and her niece 
would have undergone unnecessary surgery.
3.3 | Psychosocial impact
Few participants expressed disappointment, worry, lack of 
trust, or frustration related to their reclassification. Several 
interviewees had changed surveillance behaviors, which they 
considered minor, or had begun to pursue a prophylactic sur-
gery but had changed their mind or had received the reclas-
sification before they had undergone the intervention. These 
interviewees did not describe the reclassification as disturb-
ing nor did they consider it a medical error.
Only one participant reported undergoing an irreversible 
medical intervention based on a genetic test result that was 
later downgraded. A participant with breast cancer in her fif-
ties was initially told that she had a likely pathogenic genetic 
test result in the TP53 gene related to Li-Fraumeni Syndrome. 
Bilateral mastectomy was recommended by her surgeons, 
“and I acted on that with the knowledge of the Li-Fraumeni 
diagnosis” (24LP > U), she told us. She was called into clinic 
the following year, at which point she was informed that her 
TP53 genetic test result had been reinterpreted as a VUS, and 
that prophylactic surgeries were no longer recommended. 
She perceived that she was expected to be relieved because 
Li-Fraumeni is often considered to be a devastating diagno-
sis, but instead she and her husband “were pretty angry. […] 
It's easy to jump to ‘This was quite a mistake!’” However, 
she refused “living in a place of anger and resentment” and 
instead said that she respects the laboratory for its reclassi-
fication efforts and characterized her current feelings – now 
two years after the surgery – as ones of increased caution but 
not decreased trust. “[The reclassification] just highlighted to 
me how much is not known. […] I have a lot of respect for 
the field of medicine, [but] we can identify more than we can 
understand.”
The overall impact of reclassification on our participants’ 
relationship with the institution or medicine in general was lim-
ited. Only three (15%) participants said that the reclassification 
decreased their confidence in medical genetics. Furthermore, 
only two (10%) said that they were less confident in the ac-
curacy of their test result's interpretation at the time of the 
T A B L E  1  Participant characteristics
Participant 
characteristics N (%)
Gender Female 19 (95%)
Male 1 (5%)
Ethnicity African American 6 (30%)
Caucasian 14 (70%)





Educational attainment High school or less 1 (5%)
Some college 8 (40%)
College 2 (10%)
Graduate 9 (45%)
Clinical concerna Breast cancer 9 (45%)










aSome patients had multiple reclassifications. 
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interview, and four (20%) said that they believed the result's 
interpretation might or would likely change in the future.
3.4 | Participants often recalled little about 
reclassifications
While all respondents recalled their original test results, most 
interviewees appeared to focus limited attention on the new 
interpretation or its communication, often recalling little 
about the experience or the new information. A participant in 
her late sixties, who had a VUS downgraded to benign, de-
scribed her reclassification as follows: “I’m not saying it was 
even much of a change or any [kind] of a change. As I read it, 
it was almost like it didn't really pertain to me. […] I couldn't 
even tell you what it is” (10U > B). A woman in her mid-six-
ties, who had a result reclassified from likely pathogenic to 
pathogenic said of the updated report, “there's probably some 
fine print here, but [I’m] not seeing the difference, so what-
ever. […] To me it was, ‘We used to call it Gobbledygook, 
but now we're calling it Gobbledygook Part B’” (23LP > P).
Participants without clinically meaningful reclassifica-
tions were not the only ones who disregarded the new in-
formation they received. Six (43%) of the participants with 
clinically meaningful reclassifications that could potentially 
alter management, including VUSs downgraded to benign 
or likely benign, also expressed little interest in or under-
standing of the updated interpretation. Moreover, many par-
ticipants had little or no memory that a reclassification had 
occurred and been reported to them. “I’m sure I did” get a 
reclassification, a woman with a clinically meaningful down-
grade related to breast cancer told us (03P > U). “Maybe. I 
can't remember. Oh man, this is a whirlwind.” Three partici-
pants completely denied that their genetic test result had been 
reclassified. All three of these participants were notified of 
their reclassification by letter.
Less often, participants did remember receiving their 
results. Some of these individuals even had concrete un-
derstandings of the reinterpretation's implications for their 
health care. A woman diagnosed with pheochromocytoma 
remembered that she had initially been given “inconclusive” 
results that had been reclassified as “a recognized mutation,” 
in her own words (27U > LP). She believed the updated in-
formation was “beneficial” for herself and her family.
4 |  DISCUSSION
4.1 | Overall results
In order for genetic medicine to be successfully mainstreamed, 
patients and clinicians must understand and appreciate the un-
certainties inherent in the practice (Haga et al., 2013;Syurina, 
Brankovic, Probst-Hensch, & Brand,  2011). However, this 
area has been understudied, particularly regarding patients’ 
responses to the reclassification of their genetic test results. 
In this article – the first to focus on patients’ experiences with 
the reclassification of clinical genetic results – we describe 
many instances in which patients did not understand or recall 
the reclassification but did not necessarily experience distress.
We entered this project anticipating that participants with 
reclassifications – especially clinically meaningful reclassi-
fications in either direction – would have increased worries 
about or frustrations with genetic testing. We hypothesized 
that the notification of reclassification might decrease pa-
tients’ trust in medical genetics and that patients might have 
perceived the initial interpretation to be a medical error. 
Despite much confusion and misunderstanding, however, 
our interviewees by and large did not experience these an-
ticipated negative psychosocial outcomes. In fact, when 
participants remembered that they had received an updated 
report, they were typically pleased, feeling that the notifica-
tion demonstrated their care team's continued attention and 
concern about their well-being.
Despite having received notification of the reclassifica-
tion – often through multiple modalities – many participants 
neither remembered nor appreciated the significance of 
the reclassification for their health care. It is not necessar-
ily unanticipated that patients lack a robust recall of genetic 
test results (McCullum et  al.,  2007;Skytte et  al.,  2010;Vos 
et  al.,  2008), and we have previously shown that patients, 
especially patients with hereditary cancers, are often over-
whelmed by numerous tests, making it difficult for their al-
ready stretched emotional and energetic resources to attend to 
all relevant new information about their health and health care 
(Halverson, Wessinger, Clayton, & Wiesner, 2019). However, 
this is the first time such an issue has been demonstrated re-
garding reclassifications. A small percentage of our partici-
pants were able to articulate a concrete understanding of their 
reclassification's meaning and its consequences on their trust 
in medical genetics. Overall, however, the reclassifications 
appeared to leave little impression on our interviewees.
This is particularly concerning as reclassification is be-
coming increasingly common. A recent study found that over 
7% of over 1,600 hereditary cancer test reports had had a 
genetic variant reclassified within five years of its initial re-
port (Turner et al., 2019). Garcia and colleagues reported that 
56% of women with VUSs in BRCA genes received reclas-
sifications over a similar period (Garcia et al., 2014). Other 
studies have reported frequencies of reclassification that vary 
based on disease type, gene, and ancestry, among other fac-
tors (Baudhuin, Kluge, Kotzer, & Lagerstedt,  2019;Dong 
et  al.,  2019;Park et  al.,  2017;SoRelle, Thodeson, Arnold, 
Gotway, & Park, 2019;Wright et al., 2018).
Studies have shown that patients and clinicians have diffi-
culty understanding inconclusive genetic test results, a category 
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that includes reinterpretations (McCullum et  al.,  2007;Skytte 
et  al.,  2010;Vos et  al.,  2008). It can be challenging for both 
patients and clinicians to navigate the nuanced and evolving 
clinical relevance of genetic test results, as illustrated by the in-
terview of our participant with the downgraded TP53 variant. 
This individual's case provides a cautionary tale, as irreversible 
surgeries were performed using data that was, at the time, the 
best available to the patient and surgeon. Moreover, just because 
the variant was downgraded does not mean that it is benign.
Another lesson learned from this study relates to the 
role of laboratories in reanalyzing variants and returning 
updated interpretations. Indeed, there is no consensus re-
garding how frequently clinical genetic results should be 
reexamined or how changes should be reported (Carrieri 
et  al.,  2017;David et  al.,  2019), although many argue that 
genetic tests should be reexamined periodically and new in-
terpretations returned in both clinical and research settings 
(Bombard et  al.,  2019;Bredenoord, Onland-Moret, & Van 
Delden, 2011;Carrieri et al., 2017). While expert clinicians 
may choose to reexamine the impact of particular variants 
themselves, most reinterpretation is undertaken by laborato-
ries, which vary in whether and how they communicate new 
analyses (Chisholm et al., 2018).
The case of the participant and niece with a downgraded 
BRCA2 variant demonstrates the danger that the lack of har-
monization of classification schemes across laboratories rep-
resents. Currently, many laboratories that conduct research 
that can lead to reclassifications neither routinely reanalyze old 
patient cases nor return these results (Green et al., 2013). This 
means that data about patients’ experience with reclassifica-
tions are strikingly difficult to find. This dearth of data is wor-
rying both ethically and legally. The failure to notify a patient 
of a reclassification has already been the grounds for one law-
suit (Seymour, Case y, & Moylan, 2018), and we describe one 
participant who only learned about the reclassification from 
a relative who had been tested in another center. Inconsistent 
variant calling is a major hurdle for mainstreaming medical 
genetics, which may well be compounded with the increas-
ing use of genetic tests for diagnosis and predictive healthcare 
(Balmaña et al., 2016;Slavin, Blazer, & Weitzel, 2016). As the 
science of genetics evolves, it will become increasingly im-
portant for laboratories to be aware of differing classifications 
by competitors and to harmonize classifications accordingly. 
It will also be important for patients, their families, and their 
genetics providers to keep an open line of communication.
4.2 | Limitations of the current study
One limitation of our study is that the perceptions are based 
on participant recall and not on the actual counseling process. 
Another is that the initial testing and the reclassification noti-
fication took place several months to several years before our 
interviews. While the delay might have increased the likeli-
hood that participants did not remember or appreciate the rein-
terpretation of their results, it does reflect the reality of clinical 
genetics, where there are long gaps between testing and po-
tential reclassification. That said, all participants remembered 
at least the initial testing and return of results, which suggests 
that for many the reinterpretation was less important.
5 |  CONCLUSION
The reinterpretation of a given variant can in principle have 
a significant impact on the management of a patient's care as 
well as that of their family members. This is the first study 
that provides a real-world snapshot of patients’ perceptions 
about the reclassification of variants related to cancer sus-
ceptibility. Our participants experienced minimal harm in 
learning about their reclassifications. While some respond-
ents clearly understood the new interpretations, many of our 
interviewees expressed confusion or lack of recall about their 
reclassifications. Understanding patients' responses to reclas-
sification is therefore necessary to determine how best to re-
turn these results in a meaningful and ethical way.
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